Breast cancer now affects 1 in 8 American women and the taxane agent paclitaxel (Taxol® Bristol-Myers Squibb) is a major tool in the treatment of many such patients. Hand surgeons are therefore likely to encounter upper extremity complications related to the use of taxane therapy. We present an unusual case of a felon developing in a breast cancer patient on paclitaxel therapy with no antecedent history of trauma. Whereas onycholysis and subungual hemorrhage are reported complications of taxane therapy (Fig. 1), an acute felon with or without associated paronychia is an unusual and more aggressive manifestation of this drug-related nail dystrophy.
ConnollyBJohnstoneFGerlingerTPuttlerE. Methicillin-resistant Staphylococcus aureus in a finger felon. J Hand Surg [Am]2000;25(1):173–5.
2.
HussainSAndersonDNSalvattiMEAdamsonBMcManusMBravermanAS. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer2000;88(10):2367–71.
3.
LuftnerDFlathBAkrivakisCSchwiegertMPrinzBMergenthalerHG. Dose-intensified weekly paclitaxel induces multiple nail disorders. Ann Oncol1998;9(10):1139–40.
4.
MiglareseMRCarlsonRO. Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs2006;15(11):1411–25.
5.
MinisiniAMTostiASobreroAFMansutiMPiracciniBMSacoC. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol2003;14(2):333–7.
6.
NicolopoulosJHowardA. Docetaxel-induced nail dystrophy. Australas J Dermatol2002;43(4):293–6.
7.
PantojaECrosVFVitalePWendthAJ. Neoplastic involvement of terminal digits masquerading clinically as benign disease. Rev Interam Radiol1976;1(1):9–13.
8.
SeidmanAD. Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park)2006;20(9):983–90; discussion 991–2, 997–8.
